| Background:The fatality rate of ovarian cancer rank first of malignant tumors in gynaecology, it is serious threat to women's life and health. About 70% of ovarian cancer patients has been diagnosed during late period, mostly because of abdominal pain and gradually increase the ascites caused take seriously and see a doctor. Tumor remove is regular treatment for adjuvant chemotherapy after tumor cell reduction-extinction technique, tumor cell reduction-extinction technique can only be of utmost to remove visible tumor tissue, inevitably retain postoperative residual lesions, and therefore easily cause ovarian cancer recurrence. The chemotherapy after the traditional tumor remove treatment was less effective due to the resistance, adverse reactions and patients with low immunity and so on, result in poor prognosis of patients with late period ovarian cancer. In recent years, tumor biological therapy was high-profile, with cytokine induced killer cells(CIK) and Dendritic cells(DC) as the main research hotspot of adoptive cellular immunotherapy is a kind of tumor biological treatment is more effective in the treatment, and also a new antineoplastic plan gaining increasing attention by medical institutions. CIK cells have strong fertility and restriction of MHC and cytotoxicity, DC cells is antigen presenting cells can trigger B lymphocytes and T lymphocytes cell-mediated immune response. DC cells identify alloantigen to activate the immune system, and CIK cells can play its cytotoxicity and timely secrete relevant factor and kill tumor cells, combined DC and CIK cells, can play a role of synergy in the treatment of tumor together. So DC-CIK cells co-culture gradually show the advantage of CIK cells and DC cells together, has a high anti-tumor activity, cell surface antigen increase and improve the advantages of the immune cells, thus gradually become an important means of auxiliary treatment of tumor. DC-CIK combination therapy has been applied in lymphatic tumors, urinary system tumors, digestive system tumors, respiratory system tumor and so on, they all have achieved good results. Single cell immune therapy in the treatment of tumor areas have achieved good results, radiation and chemotherapy synergy is becoming more and more attention, for the exploring in treatment of ovarian cancer, the cellular immune therapy and chemotherapy drug therapy combined with study is less, especially for the treatment of advanced ovarian cancer field, to be more clinical research. Purpose:This research through the retrospective analysis of DC- CIK combined chemotherapy and chemotherapy alone the clinical effect and prognosis of patients with advanced ovarian cancer, providing a new method for the treatment of patients with advanced ovarian cancer and reference. Methods:In strict accordance with the standard set to choose the advanced ovarian cancer patients from January 2010 to October 2014 of first affiliated hospital of zhengzhou university as the research object, on the basis of treatment can be divided into DC-CIK chemotherapy combined group(45 cases) and pure chemotherapy group(49 cases). The immune function, serum tumor markers, adverse reactions, life quality and survival rate, etc. of two groups of patients were analyzed retrospectively and follow-up observed, to evaluate the effect of DC- CIK combined chemotherapy. Using SPSS19.0 software to statistical analysis of data, data to compare the two groups of independent sample t-test; Multiple sets of grade qualitative data using rank and inspection; Survival analysis using Kaplan-Meier survival curve drawing method, the median surial compared between the two groups in the Log- Rank test. Selection of ? = 0.05 for the inspection level, statistical results with P < 0.05 for the difference was statistically significant. Results:1.The CD3+?CD4+ and CD4+/CD8+ ratio of patients was increased in CD-CIK group after treatment with combination chemotherapy with statistical significance(P < 0.05);2.CD-CIK combined chemotherapy group and chemotherapy alone group after treatment in patients with levels of CA125, HE-4 was reduced and the and the difference was statistically significant(P < 0.05), but the DC- CIK group of patients after treatment with combination chemotherapy levels of CA125, HE- 4 level differences in the pure chemotherapy group no significant statistical significance(P > 0.05);3.Compare with CD-CIK combined chemotherapy group and chemotherapy alone group of patients with adverse reactions, the patients white blood cells of DCCIK group reduce symptoms reduced ease pure chemotherapy group, the difference was statistically significant(p = 0.032).4.Compare with the patients life quality of CD-CIK chemotherapy group and chemotherapy alone group, combination group in the field of emotional function areas of patients has improved than chemotherapy group, the difference was statistically significant(p=0.000).5.DC-CIK patients with combined chemotherapy group and chemotherapy alone group of patients with a median survival time(month) were 37±5.65,28±1.52 respectively, and the 3 years survival rate were 50.1%,±4.87, 37.9%±9.2, difference was statistically significant(p = 0.048, p = 0.043). |
PDF Full Text Request